Skip to main content
Clinical Trials/NCT04604106
NCT04604106
Unknown
Not Applicable

General Anesthesia Exposure and Neurodevelopmental Outcome in Pediatrics

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 site in 1 country70 target enrollmentOctober 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anesthesia
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Enrollment
70
Locations
1
Primary Endpoint
Neurocognitive development as measured using eye-tracking metrics
Last Updated
4 years ago

Overview

Brief Summary

This study investigates the impact of different levels of anesthesia exposure on children's neurocognitive development and evaluates the concurrent validity of different methods that assess neurodevelopmental outcome.

Detailed Description

The US Food and Drug Administration (FDA) recently released an official warning regarding the potentially harmful impact of repeated and prolonged (more than three hours) general anesthesia on the child's brain. The potential impact of anesthesia highlights the importance of remediating the need for repeated and prolonged surgery with accompanying anesthesia exposure in a time of cerebral vulnerability and if possible, delay exposure to avoid potentially preventable harm. Therefore, it is crucial to better understand the impact of (different durations and frequencies of) anesthesia exposure on neurodevelopment.

Registry
clinicaltrials.gov
Start Date
October 21, 2020
End Date
March 2023
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sanne Maat

Dr. J.P.M. Derikx

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility Criteria

Inclusion Criteria

  • Age 12 months (± four weeks) with a history of general anesthesia exposure (patient group) or without a history of general anesthesia (healthy controls)

Exclusion Criteria

  • Children with comorbid conditions affecting structure and/or function of the central nervous system (e.g. premature birth) will be excluded from participation in this study.

Outcomes

Primary Outcomes

Neurocognitive development as measured using eye-tracking metrics

Time Frame: At the age of 12 months (± four weeks)

Neurocognitive development as measured using eye-tracking metrics

Secondary Outcomes

  • Conventional measures of neurocognitive development (Ages & Stages Questionnaire and Bayley Scales of Infant Development )(At the age of 12 months (± four weeks))
  • Total anesthesia time.(At the age of 12 months (± four weeks))

Study Sites (1)

Loading locations...

Similar Trials